Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Authors: Atkins, Michael B., Lee, Sandra J., Chmielowski, Bartosz, Tarhini, Ahmad A., Cohen, Gary I., Truong, Thach-Giao, Moon, Helen H., Davar, Diwakar, O'Rourke, Mark, Stephenson, Joseph J., Curti, Brendan D., Urba, Walter J., Brell, Joanna M., Funchain, Pauline, Kendra, Kari L., Ikeguchi, Alexandra P., Jaslowski, Anthony, Bane, Charles L., Taylor, Mark A., Bajaj, Madhuri, Conry, Robert M., Ellis, Robert J., Logan, Theodore F., Laudi, Noel, Sosman, Jeffrey A., Crockett, David G., Pecora, Andrew L., Okazaki, Ian J., Reganti, Sowjanya, Chandra, Sunandana, Guild, Samantha, Chen, Helen X., Streicher, Howard Z., Wolchok, Jedd D., Ribas, Antoni, Kirkwood, John M.

Source: Journal of clinical oncology. 41(2):186-197

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100179829888.0x000001&indx=1&recIds=ETOCvdc_100179829888.0x000001

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

Authors: Timmerman, John, Herbaux, Charles, Ribrag, Vincent, Zelenetz, Andrew D., Houot, Roch, Neelapu, Sattva S., Logan, Theodore, Lossos, Izidore S., Urba, Walter, Salles, Gilles, Ramchandren, Radhakrishnan, Jacobson, Caron, Godwin, John, Carpio, Cecilia, Lathers, Deanne, Liu, Yali, Neely, Jaclyn, Suryawanshi, Satyendra, Koguchi, Yoshinobu, Levy, Ronald

Source: American journal of hematology. 95(5):510-520

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100107028795.0x000001&indx=1&recIds=ETOCvdc_100107028795.0x000001

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

Authors: Voss, Martin H., Bhatt, Rupal S., Vogelzang, Nicholas J., Fishman, Mayer, Alter, Robert S., Rini, Brian I., Beck, J. Thaddeus, Joshi, Monika, Hauke, Ralph, Atkins, Michael B., Burgess, Earle, Logan, Theodore F., Shaffer, David, Parikh, Rahul, Moazzam, Nauman, Zhang, Xiaosha, Glasser, Chad, Sherman, Matthew L., Plimack, Elizabeth R.

Source: Cancer. 125(14):2400-2408

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100084329548.0x000001&indx=1&recIds=ETOCvdc_100084329548.0x000001

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Authors: Clark, Joseph, Singh, Jatinder, Ernstoff, Marc, Lao, Christopher, Flaherty, Lawrence, Logan, Theodore, Curti, Brendan, Agarwala, Sanjiv, Taback, Bret, Cranmer, Lee, Lutzky, Jose, Luna, Theresa, Aung, Sandra, Lawson, David

Source: Journal for immunotherapy of cancer. 6(1):1-8

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100175094813.0x000001&indx=1&recIds=ETOCvdc_100175094813.0x000001

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

Authors: Weber, Jeffrey S, Gibney, Geoff, Sullivan, Ryan J, Sosman, Jeffrey A, Slingluff, Craig L, Jr, Lawrence, Donald P, Logan, Theodore F, Schuchter, Lynn M, Nair, Suresh, Fecher, Leslie, Buchbinder, Elizabeth I, Berghorn, Elmer, Ruisi, Mary, Kong, George, Jiang, Joel, Horak, Christine, Hodi, F Stephen

Source: In The Lancet Oncology July 2016 17(7):943-955

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

Authors: Armstrong, Andrew J ^*, Halabi, Susan, Eisen, Tim, Broderick, Samuel, Stadler, Walter M, Jones, Robert J, Garcia, Jorge A, Vaishampayan, Ulka N, Picus, Joel, Hawkins, Robert E, Hainsworth, John D, Kollmannsberger, Christian K, Logan, Theodore F, Puzanov, Igor, Pickering, Lisa M, Ryan, Christopher W, Protheroe, Andrew, Lusk, Christine M, Oberg, Sadie, George, Daniel J

Source: In The Lancet Oncology March 2016 17(3):378-388

Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy

Authors: Bradish, Joshua R, Richey, Justin D, Post, Kristin M, Meehan, Kari, Sen, Joyashree D, Malek, Amanda J, Katona, Terrence M, Warren, Simon, Logan, Theodore F, Fecher, Leslie A, Cheng, Liang

Source: In Modern Pathology April 2015 28(4):480-486

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

Authors: Curti, Brendan, Daniels, Gregory, McDermott, David, Clark, Joseph, Kaufman, Howard, Logan, Theodore, Singh, Jatinder, Kaur, Meenu, Luna, Theresa, Gregory, Nancy, Morse, Michael, Wong, Michael, Dutcher, Janice

Source: Journal for immunotherapy of cancer. 5(1):1-9

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100162513948.0x000001&indx=1&recIds=ETOCvdc_100162513948.0x000001

Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study

Authors: Ribas, Antoni, Gonzalez, Rene, Pavlick, Anna, Hamid, Omid, Gajewski, Thomas F, Daud, Adil, Flaherty, Lawrence, Logan, Theodore, Chmielowski, Bartosz, Lewis, Karl, Kee, Damien, Boasberg, Peter, Yin, Ming, Chan, Iris, Musib, Luna, Choong, Nicholas, Puzanov, Igor, McArthur, Grant A

Source: In Lancet Oncology August 2014 15(9):954-965

Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma

Authors: Lam, Elaine T., Wong, Michael K. K., Agarwal, Neeraj, Redman, Bruce G., Logan, Theodore, Gao, Dexiang, Flaig, Thomas W., Lewis, Karl, Poust, Jamie, Monk, Paul, Jarkowski, Anthony, Sendilnathan, Arun, Bolden, Marcus, Kuzel, Timothy M., Olencki, Thomas

Source: Journal of immunotherapy. 37(7):360-365

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCETOCvdc_100030236677.0x000001&indx=1&recIds=ETOCETOCvdc_100030236677.0x000001

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

Authors: Margolin, Kim, Ernstoff, Marc S, Hamid, Omid, Lawrence, Donald, McDermott, David, Puzanov, Igor, Wolchok, Jedd D, Clark, Joseph I, Sznol, Mario, Logan, Theodore F, Richards, Jon, Michener, Tracy, Balogh, Agnes, Heller, Kevin N, Hodi, F Stephen

Source: In Lancet Oncology May 2012 13(5):459-465

Delivery of progenitors to the thymus limits T-lineage reconstitution after bone marrow transplantation

Authors: Zlotoff, Daniel A. ^*, Zhang, Shirley L. ^*, De Obaldia, Maria Elena, Hess, Paul R., Todd, Sarah P., Logan, Theodore D., Bhandoola, Avinash ^*

Source: In Blood 18 August 2011 118(7):1962-1970

CCR7 and CCR9 together recruit hematopoietic progenitors to the adult thymus

Authors: Zlotoff, Daniel A., Sambandam, Arivazhagan, Logan, Theodore D., Bell, J. Jeremiah, Schwarz, Benjamin A., Bhandoola, Avinash

Source: In Blood 11 March 2010 115(10):1897-1905

System and method for providing an improved financial derivative product

Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study

Authors: Rini, Brian I., Halabi, Susan, Barrier, Robert, Margolin, Kim A., Avigan, David, Logan, Theodore, Stadler, Walter M., McCarthy, Philip L., Linker, Charles A., Small, Eric J.

Source: In Biology of Blood and Marrow Transplantation 2006 12(7):778-785

Nephrectomy for metastatic renal cell carcinoma: Indiana University experience

Authors: Mosharafa, Ashraf, Koch, Michael, Shalhav, Arieh, Gardner, Thomas, Logan, Theodore, Bihrle, Richard, Foster, Richard

Source: In Urology 2003 62(4):636-640

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

Authors: Ribas Antoni, Chesney Jason A, Gordon Michael S, Abernethy Amy P, Logan Theodore F, Lawson David H, Chmielowksi Bartosz, Glaspy John A, Lewis Karl, Huang Bo, Wang Erjian, Hsyu Poe-Hirr, Gomez-Navarro Jesus, Gerhardt Diana, Marshall Margaret A, Gonzalez Rene

Source: Journal of Translational Medicine, Vol 10, Iss 1, p 236 (2012)

Subject Terms: Melanoma, Tremelimumab, CTLA4, Medicine

File Description: electronic resource

Relation: http://www.translational-medicine.com/content/10/1/236; https://doaj.org/toc/1479-5876

Access URL: https://doaj.org/article/77e605fdeb0e419fa7f1fd10b3d924a9

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2 .

Authors: Clark, Joseph I., Curti, Brendan, Davis, Elizabeth J., Kaufman, Howard, Amin, Asim, Alva, Ajjai, Logan, Theodore F., Hauke, Ralph, Miletello, Gerald P., Vaishampayan, Ulka, Johnson, Douglas B., White, Richard L., Wiernik, Peter H., Dutcher, Janice P.

Source: Journal of Investigative Medicine (Sage Publications Inc.); Apr2021, Vol. 69 Issue 4, p888-892, 5p

Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003.

Authors: Dudek, Arkadiusz Z., Liu, Li C., Gupta, Shilpa, Logan, Theodore F., Singer, Eric A., Joshi, Monika, Zakharia, Yousef N., Lang, Joshua M., Schwarz, James K., Al-Janadi, Anas, Alva, Ajjai S.

Source: Journal of Clinical Oncology; 4/10/2020, Vol. 38 Issue 11, p1138-1145, 9p

Urticaria and Angioedema in Renal Cell Cancer Patients Treated with IL-2.

Authors: Logan, Theodore F.¹ (AUTHOR), Strippoli, Giovanni² (AUTHOR), Levine, Macy I.³ (AUTHOR)

Source: Cancer Investigation. Nov2007, Vol. 25 Issue 7, p584-588. 5p. 1 Black and White Photograph, 2 Charts.

Subject Terms: *INTERLEUKIN-2, *ERYTHEMA, *URTICARIA, *RENAL cell carcinoma, *SKIN tests, *ANAPHYLAXIS, *THERAPEUTICS